(Reuters) - Sanofi-Aventis SA (SASY.PA) and Genzyme Corp (GENZ.O) have reached an agreement in principle under which Sanofi will acquire Genzyme for $74 a share in cash plus a right to future payments based on the performance of Genzyme's experimental multiple sclerosis drug, according to a source with knowledge of the discussions.
